HEAD AND NECK CANCERS Updated May 2016 by Dr. Daniel Yokom (PGY 5 Medical Oncology Resident, University of Toronto)
|
|
- Thomas Richard
- 5 years ago
- Views:
Transcription
1 HEAD AND NECK CANCERS Updated May 2016 by Dr. Daniel Ykm (PGY 5 Medical Onclgy Resident, University f Trnt) Reviewed by Dr. Raymnd Jang (Staff Medical Onclgist, University f Trnt) and Dr. Desiree Ha (Staff Medical Onclgist, University f Calgary) DISCLAIMER: The fllwing are study ntes cmpiled by the abve PGY 5 medical nclgy residents and reviewed by a staff medical nclgist. They reflect what we feel is relevant knwledge fr graduating medical nclgy residents preparing fr their final examinatin. The infrmatin has nt been surveyed r ratified by the Ryal Cllege. NOTE: Head and neck squamus cell carcinma (HNSCC) and EBV related naspharyngeal carcinma (NPC) are very different and will be discussed separately Head and Neck Squamus Cell Carcinma A) PUBLIC HEALTH EPIDEMIOLOGY (1) Incidence: In 2010 ver 4000 Canadians were diagnsed with HNSCC HPV assciated HNSCC usually diagnsed at a yunger age Increasing incidence f HPV assciated HNSCC (primarily rpharyngeal) while tbacc related incidence is declining (2) Male:Female > 3:1 depending n anatmical site Mrtality: In 2010 ver 1500 Canadians died frm HNSCC RISK FACTORS Smking HPV EtOH PREVENTION & SCREENING Preventin: Smking and EtOH cessatin HPV vaccine and methds t reduce HPV expsure Screening: N screening recmmendatins in Canada r United States. B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS Cmmn Symptms: Palpable mass r lymph nde Weight lss Often depends n primary, fr example: Laryngeal: harseness r ther changes in the vice, cugh, difficult r nisy breathing Orpharyngeal: sre thrat lasting lnger than a few weeks, feeling that smething is stuck in the thrat, difficult r painful swallwing, ear pain Oral cavity: nn healing ulcer r mass INVESTIGATIONS
2 Physical exam: Oral cavity Head and neck lymph ndes Cranial nerve exam Labratry: Rutine BW, hepatitis screen Diagnstic Imaging: CT head and neck MRI neck fr rpharyngeal, may be necessary fr ther sites CT chest (stage II r higher) PET scan fr HNSCC primary unknwn CT abdmen and bne scan are nt rutinely perfrmed Diagnstic Prcedures: Endscpy and bipsy Cnsider FNA f suspicius lymph ndes fr staging Other: Ensure wmen with HPV+ HNSCC have rutine surveillance fr cervical cancer pelvic exam and pap smear. PATHOLOGY & MOLECULAR BIOLOGY Cmmn Histlgy: Vast majrity are squamus cell carcinma and discussin in this chapter pertains t SCC. Differential includes adencarcinma, melanma, sarcma, lymphma Cmmn Metastatic Sites: Lcal recurrence and lymph ndes Lung Bne Relevant Mlecular Bilgy: HPV testing using IHC fr p16(3) STAGING Staging fr HNSCC is cmplex as it is different fr each anatmical site. General rules t fllw: N1 = ne LN less than 3 cm N2a = ne LN >3 cm and < 6 cm N2b = multiple ipsilateral LN; all < 6 cm N2c = bilateral r cntralateral LN; all <6cm N3 = LN > 6cm T1 3 N1 = Stage III T1 3 N2 3 = Stage IV T4 any N = Stage IV Any distant metastatic site = Stage IVC NOTE: New staging recmmendatins fr HPV+ rpharyngeal cancer t be published in 2016 (4) C) TREATMENT EARLY STAGE Bttm Line General Apprach: Primary surgery r radical radiatin alne N rle fr chemtherapy
3 Prgnsis: 5 yr OS 56 90% depending n lcatin f the tumr LOCALLY ADVANCED Bttm Line General Apprach: Management depends n a number f factrs including anatmical site, size, invasin, c mrbidities, patient preference, etc: Cnsider discussin at a multi disciplinary tumr bard Often: Oral cavity: primary surgery fllwed by radiatin +/ chemtherapy Orpharyngeal, laryngeal, hyppharyngeal: Radiatin +/ chemtherapy, surgery fr salvage therapy nly If ges fr primary radiatin +/ cncurrent chemtherapy Radiatin: 70Gy/35# Cisplatin 100mg/m2 d1, 22, 43 (5) 50% f patients d nt get third dse Cnsider RT + weekly cisplatin 40mg/m2 fr less well patients If cisplatin cntraindicated cnsider RT + cetuximab 400mg/m2 lad (ne week prir t RT) then 250mg/m2 weekly during radiatin (6) N clear benefit fr patients ver 71 years f age area f nging research. Onging trials investigating whether less intense chemtherapy is effective fr patients with HPV+ HNSCC (7) If ges fr primary surgery then pst perative management: N adjuvant treatment if lw risk (n intermediate r high risk features) Intermediate risk: adjuvant RT alne 66Gy/33# >T2 Clse margins PNI LVI N2 r greater Level IV r V ndes High risk (8): adjuvant CRT with high dse cisplatin 100mg/m2 d1, 22, 43 Psitive margins Extracapsular spread Nte: Begin within 11 weeks f surgery Prgnsis: Better with HPV+ nn smkers(9) High risk fr secndary malignancy (usually due t life style i.e. smking) Fllw up: Imaging ~2 mnths after treatment Imprtant Phase III Clinical Trials:
4 RTOG Cncurrent chemtherapy and raditherapy fr rgan preservatin in advanced laryngeal cancer. Frastiere et al. NEJM UPDATED: Lng Term Results f RTOG 91 11: A Cmparisn f Three Nnsurgical Treatment Strategies t Preserve the Larynx in Patients With Lcally Advanced Larynx Cancer. Frastiere et al. JCO Regimen 1. Inductin cisplatin 100mg/m2 d1 plus 5 FU 1000mg/m2/d d1 5 q3w x 3 cycles fllwed by RT 70Gy/35# 2. Cncurrent cisplatin 100mg/m2 d1, 22, 43 and RT 3. RT alne Primary Endpint Laryngectmy free survival Inclusin/Exclusin Criteria Previusly untreated stage III/IV HNSCC f the larynx T1 and T4 excluded Karnfsky PPS >= 60 Size (N) 518 Results Laryngectmy Free Survival: Cncurrent CRT significantly imprved LFS HR 0.58 (95% CI , p=0.005) Overall Survival : N difference althugh trend twards wrse with cncurrent CRT HR 1.25 (95% CI , p=0.08) cmpared t inductin chemtherapy Txicity Cncurrent CRT mre txic: stmatitis (43% vs 20%), esphagitis (35% vs 19%), nausea/vmiting (20% vs 14%) Cnclusin Cncurrent CRT imprved laryngectmy free survival with n imprvement in OS Other Cmments 70% f patients in cncurrent CRT arm received 3 cycles f cisplatin (mre than real wrld numbers) Raditherapy plus cetuximab fr squamus cell carcinma f the head and neck. Bnner et al. NEJM Regimen 1. RT alne, 70 76Gy 2. RT plus Cetuximab (400mg/m2 lad 1 week prir t RT then 250mg/m2 weekly during RT) Primary Endpint Lcreginal cntrl Inclusin/Exclusin Criteria Previusly untreated stage III/IV nn metastatic HNSCC f the rpharynx, hyppharynx r larynx Karnfsky PPS >= 60 Nrmal hematpietic, hepatic and renal functin Size (N) 424 Results Lcreginal cntrl: RT+cetux significantly imprved lcreginal prgressin median 24.4m vs 14.9m, HR 0.68 (95% CI , p=0.005) Overall Survival : RT+cetux significantly imprved median survival 49.0 vs 29.3 m (p=0.03), 3 y OS 55% vs 45% (p=0.05), HR 0.74 (95% CI ) Txicity acneifrm rash: 87% vs 10% all grades, 17% gr 3 5 infusin reactin: 15% vs 2% all grades, 3% vs 0% gr 3 5 ther mild side effects f cetuximab: weight lss, headache, nausea Cnclusin RT+cetux imprves lcreginal cntrl and verall survival cmpared t RT alne Other Imprtant Published Data fr HNSCC:
5 Defining risk levels in lcally advanced head and neck cancers: A cmparative analysis f cncurrent pstperative radiatin plus chemtherapy trials f the EORTC (#22931) and RTOG (#9501). Bernier et al. Head & Neck Methds: Results Analysis f pled data frm EORTC (10) and RTOG 9501 (11,12). Bth studies cmpared pst surgery adjuvant radiatin t adjuvant chemradiatin with high dse cisplatin (100mg/m2 d1,22,43) in patients with high risk features. Patients wh benefit frm additin f adjuvant high dse cisplatin t radiatin include thse with features f psitive margins and/r extracapsular extensin frm lymph ndes Patients withut these features had n survival advantage with additin f chemtherapy Bttm line Patients with psitive margins and/r extracapsular extensin have imprved survival with additin f cisplatin t radiatin. Meta analysis f chemtherapy in head and neck cancer (MACH NC): An update n 93 randmised trials and 17,346 patients. Pignn et al. Raditherapy and Onclgy Methds: Individual patient data frm trials cmparing lc reginal treatment f radiatin with r withut chemtherapy Results 87 trials with 16,485 individual patients included HR fr death = 0.88 (p < ) fr additin f any chemtherapy, 5 year abslute survival benefit f 4.5% (p < ) Cncurrent CRT better than sequential (either inductin r adjuvant) HR fr death = 0.81 fr cncurrent CRT, 5 year abslute survival benefit = 6.5% Decreasing benefit with age, particularly >70y Bttm line Significant benefit f cncurrent CRT Cnsider RT alne fr patients >70y Ntes Trials f NPC nly were excluded Meta analysis f chemtherapy in head and neck cancer (MACH NC): A cmprehensive analysis by tumur site. Blanchard et al. Raditherapy and Onclgy Methds: Individual patient data frm trials cmparing lc reginal treatment f radiatin with r withut chemtherapy Patients divided int 4 tumr lcatins: ral cavity, rpharynx, hyppharynx and larynx Other tumr lcatins were excluded Results 87 trials with 16,192 individual patients included Additin f chemtherapy beneficial fr all sites Cncurrent CRT better than sequential statistically fr rpharyngeal and laryngeal nly. 5 year OS benefits f cncurrent vs sequential: 8.9% ral cavity (p = 0.15) 8.1% rpharynx (p < ) 5.4% larynx (p = 0.05) 4% hyppharynx (p = 0.31) Bttm line
6 Significant benefit f chemtherapy fr all anatmical sites Cncurrent better fr rpharyngeal and laryngeal and likely als fr ral cavity and hyppharynx althugh nt statistically significant SUPPORTIVE MEASURES Cnsults: All patients shuld be referred t a dietitian and cnsidered fr a feeding tube Assess weight prir t each chem dse, >10% weight lss is cncerning SLP Dentistry Smking cessatin Cnsider hearing test Hydratin METASTATIC Patients n high dse cisplatin require significant hydratin at hme r sme centres chse t admit patients t hspital Bttm Line General Apprach: Cnsider salvage surgery r radiatin First line is cisplatin 75mg/m2 d1 and 5 FU 1000mg/m2/d d1 4 q3 4w Cnsider splitting cisplatin 25mg/m2/d d1 3 Other first line regimens: weekly cisplatin, carbplatin + paclitaxel Cetuximab added t platinum + 5 FU in sme places based n EXTREME trial(13) but nt funded in Ontari N evidence fr survival fr secnd line treatments but reasnable ptin is dcetaxel Evidence fr nivlumab in secnd line will be available in 2016 Prgnsis: Median OS 6 9 mnths, better in HPV related disease Imprtant Phase III Clinical Trials: EXTREME Trial Platinum Based Chemtherapy plus Cetuximab in Head and Neck Cancer. Vermrken et al. NEJM Regimen Platinum (cis r carb) plus 5 FU with r withut cetuximab (400mg/m2 lad then 250mg/m2 weekly) MOA f EGFR inhibitr Experimental Drug Primary Endpint OS Inclusin/Exclusin Recurrent r metastatic HNSCC Criteria Karnfsky PS >=70 Size (N) 442 Results Survival : Cetuximab imprved median OS by 2.5 mnths (10.1 vs 7.4, p=0.04), HR fr death 0.80 PFS: Cetuximab imprved median PFS (5.6 vs 3.3 mnths, p<0.001) Respnse Rate: Cetuximab imprved RR (36% vs 20%, p<0.001) Txicity Cetuximab arm had 9% grade 3 rash, therwise similar txicity Cnclusin Additin f cetuximab t first line platinum based chemtherapy fr patients with metastatic HNSCC prvides a small but significant increase in OS, PFS and RR. Other Cmments Similar study with panitumumab was negative(14)
7 Naspharyngeal Carcinma A) PUBLIC HEALTH EPIDEMIOLOGY (1) Incidence: Rare: <1:100,000/yr in Nrth America, up t 65:100,000 amng patients in Nrthern Africa, Suthern China and Sutheast Asia. In Canadians were diagnsed with NPC Male:Female = 2:1 Mrtality: In Canadians died frm NPC RISK FACTORS NPC Mst cmmn in Sutheast Asian and Chinese ancestry Epstein Barr virus Salted fish and meat Smking PREVENTION & SCREENING Preventin: Smking cessatin Reduce intake f salted fish and meat Reduce ccupatinal expsures Screening: N screening recmmendatins in Canada r United States. B) PRESENTATION & DIAGNOSIS SYMPTOMS & SIGNS Cmmn Symptms: Palpable mass r lymphadenpathy Nasal symptms: nse bleeds r bldy discharge frm the nse, stuffiness r blckage in the nse Ear symptms: pain r blckage in ne ear, persistent infectins in ne ear, ringing in the ear, r tinnitus, hearing difficulties r hearing lss Eye symptms: bulging eye, diplpia trismus, sre thrat, facial pain, headache, cranial nerve deficits weight lss INVESTIGATIONS
8 Physical exam Labratry: Rutine BW, hepatitis screen EBV level Diagnstic Imaging: CT head and neck MRI neck CT chest PET scan if n bvius metastases CT abdmen and bne scan are nt rutinely perfrmed Diagnstic Prcedures: Endscpy Bipsy/FNA, EBER n tumr PATHOLOGY & MOLECULAR BIOLOGY Cmmn Histlgy: Keratinizing squamus cell carcinma (WHO type I) Differentiated nn keratinizing carcinma (WHO type II) Strngest relatinship with EBV Undifferentiated carcinma (WHO type III) Cmmn Metastatic Sites: Lcal recurrence Lung Bne Relevant Mlecular Bilgy: STAGING C) TREATMENT LOCALIZED / ADJUVANT / RESECTABLE Bttm Line General Apprach: Stage I Radiatin t primary (70Gy/35#) Stage II Radiatin plus high dse cisplatin (100mg/m2) +/ adjuvant chemtherapy Prgnsis: 5 yr OS 70 90%
9 Imprtant Phase III Clinical Trials fr NPC: Cncurrent Chemraditherapy vs Raditherapy Alne in Stage II Naspharyngeal Carcinma: Phase III Randmized Trial. Chen et al. JNCI Regimen Raditherapy alne Raditherapy plus cisplatin 30mg/m2 weekly Primary Endpint OS Inclusin/Exclusin Chinese 1992 stage II NPC Criteria Size (N) 230 Results Survival : Chemtherapy HR fr death = 0.3 (95%CI , p=0.007), 5 yr OS abslute benefit f 8.7% (94.5% vs 85.8%) Txicity Increased early txicity (neutrpenia, nausea/vmiting, mucsitis) N difference in late txicity Cnclusin Additin f weekly cisplatin cncurrently with raditherapy imprves verall survival in patients with stage II NPC Other Cmments If reclassified t AJCC staging then abut 85% stage II, 15% stage III, slightly mre stage III were in the CRT grup LOCALLY ADVANCED / UNRESECTABLE Bttm Line General Apprach fr NPC Stage III IV: Cncurrent chemradiatin as per CCO guidelines(15) Benefit f adjuvant chem in additin t CRT is currently being investigated with multiple nging phase III studies CRT and adjuvant chem: Radiatin: 70Gy/35#, cisplatin 100mg/m2 d1, 22, 43 then adjuvant chem 4 weeks pst radiatin cisplatin 80mg/m2 d1 plus 5 FU 1000mg/m2/d d1 4, q28d x 3 cycles Cnsider CRT alne: Cisplatin 20mg/m2/d and 5 FU 400mg/m2/d cntinuus fr 96hrs d1 4 and Prgnsis: 5 yr OS: 45 62% Fllw up: Imaging ~2 mnths after treatment Imprtant phase III clinical trials fr NPC: Intergrup 0099 Chemraditherapy versus raditherapy in patients with advanced naspharyngeal cancer: phase III randmized Intergrup study Al Sarraf et al. J Clin Oncl Regimen RT 70Gy/35# +/ cisplatin 100mg/m2 d1,22,43 then pst raditherapy cisplatin 80mg/m2 d1 and 5 FU 1000mg/m2/d d1 4 q4w x 3 cycles Primary Endpint PFS Inclusin/Exclusin Stage III IV Criteria Size (N) 193 Results 3 yr PFS: imprved in chemtherapy arm (69% vs 24%, p<0.001) 3 yr OS: imprved in chemtherapy arm (78% vs 47%, p=0.005) Cnclusin Additin f chemtherapy t raditherapy significantly prlnged PFS and OS in patients with lcally advanced NPC
10 Other Imprtant Published Data fr NPC: Cncurrent chemraditherapy plus adjuvant chemtherapy versus cncurrent chemraditherapy alne in patients with lcreginally advanced naspharyngeal carcinma: a phase 3 multicentre randmised cntrlled trial. Chen et al. Lancet Oncl Methds: Phase III RCT f cncurrent radiatin (66Gy/33#) plus weekly cisplatin (40mg/m2) with r withut adjuvant cisplatin (80mg/m2 d1) and 5 FU (800mg/m2/d d1 4) q4w x 3 cycles Primary end pint was failure free survival Results 508 patients enrlled N difference in 2 yr failure free survival (86% vs 84%, p=0.13) N difference in txicity Bttm line N benefit f adding adjuvant cisplatin and 5 FU t CRT fr lcally advanced NPC Nte Early results published, final results are pending Chemtherapy and raditherapy in naspharyngeal carcinma: an update f the MAC NPC meta analysis. Blanchard et al. Lancet Onclgy Methds: Individual patient data frm trials cmparing treatment f radiatin with r withut chemtherapy fr lcally advanced NPC, updated frm 2006 meta analysis. Included interactin testing fr different schedules f chemtherapy Results 19 trials with 4806 individual patients included Pled HR fr death 0.79 (95%CI , p<0.0001) Abslute 5 yr OS benefit f chemtherapy is 6.3% Cncurrent chemtherapy with r withut adjuvant chemtherapy is better than adjuvant alne r inductin alne (p=0.01) Bttm line Cncurrent chemradiatin significantly imprves OS, PFS and lcal cntrl in patients with lcally advanced NPC. Additin f adjuvant chemtherapy t chemradiatin f unclear benefit, nn significant trend twards imprvement with adjuvant chemtherapy. Minimal r n benefit with inductin chemtherapy r adjuvant chemtherapy alne SUPPORTIVE MEASURES Refer t supprtive measures fr HNSCC METASTATIC Bttm Line General Apprach: Cnsider salvage surgery r radiatin N randmized evidence, cnsider clinical trial Cisplatin and gemcitabine typically given as first line, ne pssible regimen is: Cisplatin 70mg/m2 d1 and gemcitabine 1000mg/m2 d1 and 8 q21d Other first line regimens: carbplatin and gemcitabine, cisplatin and 5 FU, cisplatin and paclitaxel, weekly cisplatin, capecitabine Prgnsis: 5 yr OS 20% Other Imprtant Published Data fr NPC:
11 Cmparisn f five cisplatin based regimens frequently used as the first line prtcls in metastatic naspharyngeal carcinma. Jin et al. J Cancer Res Clin Oncl Methds: Retrspective review f 822 patients with metastatic r recurrent NPC Results Five cmmn treatments: cisplatin plus gemcitabine, cisplatin plus 5 FU, cisplatin plus paclitaxel, cisplatin plus paclitaxel plus 5 FU and cisplatin plus 5 FU plus blemycin. Highest RR with cis gem (71.1%), statistically significant ver cis 5 FU (60.2%), p= N difference in PFS r OS. Mre txicity with three drug regimens. Bttm line Cis gem, cis 5 FU and cis paclitaxel are all active regimens fr metastatic NPC N benefit fr three drugs ver tw. D) REFERENCES 1. Canadian Cancer Sciety. Canadian Cancer Statistics 2015: Special tpic: Predictins f the future burden f cancer in Canada. 2015; 2. Frte T, Niu J, Lckwd GA, Bryant HE. Incidence trends in head and neck cancers and human papillmavirus (HPV) assciated rpharyngeal cancer in Canada, Cancer Causes Cntrl Aug;23(8): Gilbert R, Winquist E, Waldrn J, Mcquestin M. The Management f Head and Neck Cancer in Ontari : Organizatinal and Clinical Practice Guideline Recmmendatins O Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrm K, et al. Develpment and validatin f a staging system fr HPV related rpharyngeal cancer by the Internatinal Cllabratin n Orpharyngeal cancer Netwrk fr Staging (ICON S): a multicentre chrt study. Lancet Oncl Feb 26;17(4): Adelstein DJ, Li Y, Adams GL, Wagner H, Kish J a, Ensley JF, et al. An intergrup phase III cmparisn f standard radiatin therapy and tw schedules f cncurrent chemraditherapy in patients with unresectable squamus cell head and neck cancer. J Clin Oncl. 2003;21(1): Bnner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Chen RB, et al. Raditherapy plus Cetuximab fr Squamus Cell Carcinma f the Head and Neck. N Engl J Med Feb 9;354(6): O Sullivan B, Huang SH, Siu LL, Waldrn J, Zha H, Perez Ordnez B, et al. Deintensificatin candidate subgrups in human papillmavirus related rpharyngeal cancer accrding t minimal risk f distant metastasis. J Clin Oncl Feb 10;31(5): Bernier J, Cper JS, Pajak TF, van Glabbeke M, Burhis J, Frastiere A, et al. Defining risk levels in lcally advanced head and neck cancers: a cmparative analysis f cncurrent pstperative radiatin plus chemtherapy trials f the EORTC (#22931) and RTOG (# 9501). Head Neck Oct;27(10): Ang KK, Harris J, Wheeler R, Weber R, Rsenthal DI, Nguyen Tân PF, et al. Human papillmavirus and survival f patients with rpharyngeal cancer. N Engl J Med Jul 1;363(1): Bernier J, Dmenge C, Ozsahin M, Matuszewska K, Lefèbvre J L, Greiner RH, et al. Pstperative irradiatin with r withut cncmitant chemtherapy fr lcally advanced head and neck cancer. N Engl J Med. 2004;350(19): Cper JS, Pajak TF, Frastiere AA, Jacbs J, Campbell BH, Saxman SB, et al. Pstperative cncurrent raditherapy and chemtherapy fr high risk squamus cell carcinma f the head and neck. N Engl J Med May 6;350(19): Cper JS, Zhang Q, Pajak TF, Frastiere AA, Jacbs J, Saxman SB, et al. Lng term fllw up f the RTOG 9501/intergrup phase III trial: pstperative cncurrent radiatin therapy and chemtherapy in high risk squamus cell carcinma f the head and neck. Int J Radiat Oncl Bil Phys Dec 1;84(5): Vermrken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rttey S, et al. Platinum based
12 chemtherapy plus cetuximab in head and neck cancer. N Engl J Med Sep 11;359(11): Vermrken JB, Stöhlmacher Williams J, Davidenk I, Licitra L, Winquist E, Villanueva C, et al. Cisplatin and flururacil with r withut panitumumab in patients with recurrent r metastatic squamus cell carcinma f the head and neck (SPECTRUM): an pen label phase 3 randmised trial. Lancet Oncl Jul;14(8): Thephamngkhl K, Brwman G, Hdsn I, Oliver T, Zuraw L. A Quality Initiative f the Prgram in Evidence based Care (PEBC), Cancer Care Ontari (CCO) Naspharyngeal Cancer
BACKGROUND Head and neck cancers can arise in the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyoroid, and salivary glands
HEAD AND NECK CANCERS Updated May 2017 by Dr. Di (Maria) Jiang (PGY-5 Medical Onclgy Resident, University f Trnt) DISCLAIMER: The fllwing are study ntes cmpiled by the abve PGY-5 medical nclgy residents
More informationFour categories which guide further evaluation
Unknwn Primary Updated May 2017 by Di Maria Jiang (PGY-5 Medical Onclgy Resident, University f Trnt) Reviewed by Dr. Chistine Elser (Staff Medical Onclgist, University f Trnt) and Dr. Sct Dwden (Staff
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationVolume Measurement at CT
Vlume Measurement at CT Staging and Assessment f Respnse with Quantitative CT Lawrence Schwartz, MD Department f Radilgy Clumbia University Cllege f Physicians and Surgens LSCHWARTZ@COLUMBIA.EDU Recmmendatins
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More informationHealth Science Ch. 16 Cancer Lecture Outline
Cancer Leading cause f disease-related death amng peple under age 75 Secnd leading cause f death Evidence supprts that mst cancers culd be prevented by simple lifestyle changes Tbacc is respnsible fr abut
More informationMACH-NC3-induction. Meta-analysis of Taxane-cisplatin-5FU as Induction Chemotherapy in locally advanced Head and neck squamous cell carcinoma
MACH-NC Meta-Analysis f Chemtherapy in Head & Neck Cancer MACH-NC3-inductin Meta-analysis f Taxane-cisplatin-5FU as Inductin Chemtherapy in lcally advanced Head and neck squamus cell carcinma Initiated
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationLung cancer. Lung cancer basics
Onclgy cre learning series by Harmesh R. Naik, MD. Lung cancer Lung cancer basics Incidence: A wrldwide epidemic : Mre than 1 millin new cases per year and mre than 900,000 deaths annually. Overall mrtality
More informationStudy Design Open, three arm-stratified, non-randomized, prospective, multicentric study
PONS Study Synpsis Title f the Study Subtype-Stratified Fllw-up Care Study f Breast Cancer Patients with Cmbined In Vitr and In Viv Diagnstics Plus Early Target-Oriented Interventin Gals Imprve and individualize
More informationACRIN 6666 Screening Breast US Follow-up Assessment Form
Screening Breast US Fllw-up Assessment Frm N. Instructins: The frm is cmpleted at 12, 24 and 36 mnths pst initial n study mammgraphy and ultrasund by the Radilgist r RA. Reprt all interim infrmatin related
More informationHuman papillomavirus (HPV) refers to a group of more than 150 related viruses.
HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between
More informationCancer of Unknown Primary (CUP) Pathways and Guidelines (v 2) London Cancer. April 2017
Cancer f Unknwn Primary (CUP) Pathways and Guidelines (v 2) Lndn Cancer April 2017 The fllwing pathways and guidelines dcument has been cmpiled by the Lndn Cancer CUP technical subgrup and agreed by the
More informationReviewed by Dr. Nimira Alimohammed (Staff Oncologist, University of Calgary) and Dr. Scott Berry (Staff Oncologist, University of Toronto) in 2016
PROSTATE CANCER Updated January 2016 by Dr. Kristy Wassn (PGY-5 Medical Onclgy Resident, University f Trnt) and August 2017 by Dr. Jenny K (Staff Onclgist, Abbtsfrd Cancer Centre, BCCA) Reviewed by Dr.
More informationCERVICAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
1 CERVICAL CANCER Updated Apr 2017 by: Dr. Jenny K (Medical Onclgist, Abbtsfrd Cancer Centre) Surce: UpTDate 2017, ASCO/CCO/Alberta prvincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gyneclgic Onclgist,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationSafety of HPV vaccination: A FIGO STATEMENT
FIGO Statement n HPV Vaccinatin Safety, August 2nd, 2013 Safety f HPV vaccinatin: A FIGO STATEMENT July, 2013 Human papillmavirus vaccines are used in many cuntries; glbally, mre than 175 millin dses have
More informationHODGKIN S LYMPHOMA (HODGKIN S DISEASE)
HODGKIN S LYMPHOMA (HODGKIN S DISEASE) LYMPHOMAS GENERAL One f the mst curable and treatable malignancy Diverse grup f disrders Lymphma bilgy and management has led t several majr breakthrughs in cancer
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationField Epidemiology Training Program
Field Epidemilgy Training Prgram Cancer Curriculum: Principles f Cancer Registries Case Study: Hspital-Based Cancer Registries FACILITATOR GUIDE FETP Cancer Curriculum: Principles f Cancer Registries Case
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. Over the last several mnths, the United States has experienced a natinwide utbreak f entervirus D68 (EV- D68) assciated
More informationKey Points Enterovirus D68 in the United States, 2014 Note: Newly added information is in red.
Key Pints Entervirus D68 in the United States, 2014 Nte: Newly added infrmatin is in red. The United States is currently experiencing a natinwide utbreak f entervirus D68 (EV-D68) assciated with severe
More informationCLL Updated February 2016 by Dr. Manna (PGY 5 Hematology Resident, University of Calgary)
CLL Updated February 2016 by Dr. Manna (PGY 5 Hematlgy Resident, University f Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematlgist, University f Calgary) and Dr. Matt Cheung (Staff Hematlgist, University
More informationCNS Updated December 2015 by Dr. Carrie Yeung (PGY-5 Medical Oncology Resident, University of Toronto)
CNS Updated December 2015 by Dr. Carrie Yeung (PGY-5 Medical Onclgy Resident, University f Trnt) Reviewed by Dr. Rger Tsang (Staff Medical Onclgist, University f Calgary) and Dr. Warren Masn (Staff Medical
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationBRCA1 and BRCA2 Mutations
BRCA1 and BRCA2 Mutatins ROBERT LEVITT, MD JESSICA BERGER-WEISS, MD ADRIENNE POTTS, MD HARTAJ POWELL, MD, MPH COURTNEY LEVENSON, MD LAUREN BURNS, MSN, RN, WHNP OBGYNCWC.COM v Cancer is a cmplex disease
More informationNonclinical factors associated with premature termination of adjuvant chemotherapy for stage I-III breast cancer
Nnclinical factrs assciated with premature terminatin f adjuvant chemtherapy fr stage I-III breast cancer Xia-Cheng Wu, Trevr Thmpsn, Meichin Hsieh, Meijia Zhu, Patricia Andrews, Michelle Lch, Timthy Styles,
More informationdecreased when the man lies down. The varicocele cannot usually be palpated lying down.
Variccele - Management View full scenari Hw d I knw my patient has a variccele? The man may present with cncern abut scrtal swelling r scrtal pain, r a variccele may be an incidental finding n physical
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationCDC Influenza Division Key Points MMWR Updates February 20, 2014
CDC Influenza Divisin Key Pints MMWR Updates In this dcument: Summary Key Messages Seasnal Influenza Vaccine Effectiveness: Interim Adjusted Estimates Influenza Surveillance Update: September 29, 2013-February
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationCHEMOPREVENTION in BREAST CANCER
CHEMOPREVENTION in BREAST CANCER Ozlem Er, M.D. Assc Prf f Medical Onclgy ESMO Curse Essentials f Medical Onclgy Outline Risk Assessment Mlecular Targets ER psitive Breast Cancer Tamxifen Ralxifene Lasfxifene
More informationIowa Early Periodic Screening, Diagnosis and Treatment Care for Kids Program Provider Training
Iwa Early Peridic Screening, Diagnsis and Treatment Care fr Kids Prgram Prvider Training The Early Peridic Screening, Diagnsis and Treatment (EPSDT) Care fr Kids prgram is Iwa s Medicaid prgram fr children.
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationA foot x-ray series is required only if there is pain in the midfoot zone and any one of the following:
RADIOGRAPHY OF THE ANKLE AND FOOT (OTTAWA ANKLE RULES) Clinical Practice Guideline January 2007 This guideline has been adapted frm the Ottawa Ankle Rules develped by Dr. Ian Stiell et al. Dr. Stiell received
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationConsensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline
Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders
More informationAdult Preventive Care Guidelines
Adult Preventive Care Guidelines Gundersen is yur partner fr better health. We want t wrk with yu t make sure that yu and yur family are as healthy as pssible. That can be accmplished best if we wrk tgether
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationRisk factors in health and disease
Risk factrs in health and disease Index 1 Intrductin 2 Types f risk factrs 2.1 Behaviural risk factrs 2.2 Psychlgical risk factrs 2.3 Demgraphic risk factrs 2.4 Envirnmental risk factrs 2.5 Genetic risk
More informationCONTACT: Amber Hamilton TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW
FACT SHEET CONTACT: Amber Hamiltn 212-266-0062 TYPE 2 DIABETES AND OBESITY: TWIN EPIDEMICS OVERVIEW Type 2 diabetes accunts fr 90-95% f the 29.1 millin diabetes cases in the U.S. 1 Obesity is a majr independent
More informationProtocol Abstract and Schema
NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD-0332991 (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central
More informationAssessing guideline impact on referral patterns of postprostatectomy patients to radiation oncologists
Original research Assessing guideline impact n referral patterns f pstprstatectmy patients t radiatin nclgists Amandeep Taggar, MD; 1 Majed Alghamdi, MD; 1 Derek Tilly, MD; 2 Xanthula Kstaras, MD; 2 Marc
More informationLocally advanced head and neck cancer
Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary
More informationInternational Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma 1
Internatinal Myelma Wrking Grup Guidelines n Imaging Techniques in the Diagnsis and Mnitring f Multiple Myelma 1 Up t 90% f myelma patients develp stelytic lesins, a majr cause f mrbidity and mrtality,
More informationOsteoporosis Fast Facts
Osteprsis Fast Facts Fast Facts n Osteprsis Definitin Osteprsis, r prus bne, is a disease characterized by lw bne mass and structural deteriratin f bne tissue, leading t bne fragility and an increased
More informationTRANSPLANTATION AND CLINICAL IMMUNOLOGY. Proceedings of the Twenty-Second International Course, Lyon, May 1990
-----.---.----~ Reprinted frm: TRANSPLANTATION AND CLINICAL IMMUNOLOGY VOLUME XXII Multiple Transplants Prceedings f the Twenty-Secnd Internatinal Curse, Lyn, 2-23 May 99 This publicatin was made pssible
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationXX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Pembrlizumab NDC CODE(S) 00006-3026-XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME) DESCRIPTION Pembrlizumab is a human prgrammed death
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationXX Abraxane 100 MG SUSR (CELGENE CORP
Medical Manual Apprved Revised: D Nt Implement until 6/30/2019 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationHarold P. Adams, Jr., MD Department of Neurology Carver College of Medicine UIHC Comprehensive Stroke Center University of Iowa
Harld P. Adams, Jr., MD Department f Neurlgy Carver Cllege f Medicine UIHC Cmprehensive Strke Center University f Iwa D nt receive persnal cmpensatin frm cmmercial interests D receive grant supprt frm
More informationHEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING. Public Health Relevance. Highlights.
HEALTH SURVEILLANCE INDICATORS: CERVICAL CANCER SCREENING Public Health Relevance Cervical cancer is 90% preventable by having regular Papaniclau (Pap) tests. The Pap test, als knwn as a cervical smear,
More informationScreening Questions to Ask Patients
Screening Questins t Ask Patients 1. Have yu ever had TB (Tuberculsis)? Yes N 2. Have yu been living with anyne in the past tw years that has been diagnsed with TB? Yes N 3. Have yu ever had a Persistent
More informationCOLORECTAL CANCER Updated April 2016 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
COLORECTAL CANCER Updated April 2016 by Dr. Dreen Ezeife (PGY-5 Medical Onclgy Resident, University f Calgary) Reviewed by Dr. Sctt Berry (Staff Medical Onclgist, University f Trnt) DISCLAIMER: The fllwing
More informationSUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY
EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY SUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY Sme 50% f cancers that affect wmen are lcated in the breast r in the genital rgans. Gynaeclgical
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More informationMeasures to Minimize Influenza Transmission at Swine Exhibitions
Measures t Minimize Influenza Transmissin at Swine Exhibitins It is estimated that 150 millin peple visit agricultural fairs each year in Nrth America. Agricultural exhibitins prvide valuable educatinal
More informationObesity/Morbid Obesity/BMI
Obesity/mrbid besity/bdy mass index (adult) Obesity/Mrbid Obesity/BMI Definitins and backgrund Diagnsis cde assignment is based n the prvider s clinical judgment and crrespnding medical recrd dcumentatin
More informationBREAST CANCER Updated June 2016 by Dr. Nixon (PGY-5 Medical Oncology Resident, University of Calgary)
BREAST CANCER Updated June 2016 by Dr. Nixn (PGY-5 Medical Onclgy Resident, University f Calgary) Reviewed by Dr. Jan-Willem Henning (Staff Medical Onclgist, Tm Baker Cancer Centre, University f Calgary),
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More information2. How are screening and diagnostic mammograms different?
Mammgrams cmprises public dmain material frm the Natinal Cancer Institute at the Natinal Institutes f Health, an agency f the U.S. Department f Health and Human Services. Mammgrams Key Pints A mammgram
More informationNasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)
Nasopharynx Cancer 1 Feb 2016 Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Expert Panels Prof Mo Mo Tin Prof Michael Boyer Dr Raewyn Campbell Prof
More informationInfluenza (Flu) Fact Sheet
Influenza (Flu) Fact Sheet What is the flu? The flu is a cntagius respiratry illness caused by influenza viruses. It can cause mild t severe illness, and at times can lead t death. Sme peple, such as lder
More informationThe principles of evidence-based medicine
The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t
More informationMEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injection for intravenous infusion
MEDICATION GUIDE LEMTRADA (lem-tra-da) (alemtuzumab) Injectin fr intravenus infusin Read this Medicatin Guide befre yu start receiving LEMTRADA and befre yu begin each treatment curse. There may be new
More informationTASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE
Sunday 19 July, 2015 TASKFORCE REPORT AIMS TO BOOST CANCER SURVIVAL AND TRANSFORM PATIENT EXPERIENCE SIX STRATEGIC pririties have tday (Sunday) been recmmended by the Independent Cancer Taskfrce t help
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationGuideline Number: NIA_CG_301 Last Revised Date: October 2014 Responsible Department: Implementation Date: October 2014 Clinical Operations
Natinal Imaging Assciates, Inc. Clinical guidelines PARAVERTEBRAL FACET JOINT INJECTIONS OR BLOCKS CPT Cdes: Cervical Thracic Regin: 64490 (+ 64491, +64492), 0213T (+0214T, +0215T) Lumbar Sacral Regin:
More informationNeoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD
Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:
More informationReference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57
Reference: Patient A Brenda WXXXXX Date f Birth: 4/15/57 49 year ld white female patient presented n July 20, 2006 with chief cmplaint f stage 4 cancer, initially diagnsed in Octber, 2003 with Cervical
More informationctdna-guided Change of Therapy Improves Quality of Life of a Lung Cancer Patient
CASE STUDY ctdna-guided Change f Therapy Imprves Quality f Life f a Lung Cancer Patient Quick Summary Tripti Vasudev*, aged 61 years, was diagnsed with NSCLC. Genetic analysis revealed the presence f an
More informationChapter 6: Impact Indicators
Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the
More informationHead and neck cancers are often treated with radiotherapy. Radiotherapy can lead to faster rates of tooth decay and poor healing in the mouth.
DENTAL EXTRACTION This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins that
More informationMedication Assisted Treatment for Opioid Use Disorder in Rural Colorado
Medicatin Assisted Treatment fr Opiid Use Disrder in Rural Clrad Why is piid use disrder getting s much attentin? Opiid Use Disrder (OUD) has seen an epidemic rise in the United States ver the past decade.
More informationPHARYNGO-OESOPHAGECTOMY
PHARYNGO-OESOPHAGECTOMY This infrmatin aims t help yu understand the peratin, what is invlved and sme cmmn cmplicatins that may ccur. It may help answer sme f yur questins and help yu think f ther questins
More informationReviewed by Dr. Jose Monzon (Medical Oncologist, Tom Baker Cancer Centre, University of Calgary)
SQUAMOUS CELL, BASAL CELL AND OTHER RARE NON MELANOMA SKIN CANCER Updated December 2015 by Dr. Ines Menjak (PGY 5 Medical Onclgy Resident, University f Trnt) Reviewed by Dr. Jse Mnzn (Medical Onclgist,
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationFrequently asked questions: Influenza A (H1N1)v
July 30 th 2009 V1.0 Frequently asked questins: Influenza A (H1N1)v (Swine Flu) infrmatin fr parents The fllwing advice is fr parents f children in all educatinal institutins, including crèches, childcare,
More informationPage 1 of 5. Fast Facts. CTC v.4; AJCC 7 th ed. Herceptin provided
Page 1 f 5 NSABP B-47 - A Randmized Phase III Trial f Adjuvant Therapy Cmparing Chemtherapy Alne (Six Cycles f Dcetaxel Plus Cyclphsphamide r Fur Cycles f Dxrubicin Plus Cyclphsphamide Fllwed by Weekly
More informationMEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidomide) capsules What is the most important information I should know about REVLIMID?
MEDICATION GUIDE REVLIMID (rev-li-mid) (lenalidmide) capsules What is the mst imprtant infrmatin I shuld knw abut REVLIMID? Befre yu begin taking REVLIMID, yu must read and agree t all f the instructins
More informationMedical Policy Manual Approved Revised Policy: Do Not Implement Until 3/2/19
Plicy Medical Plicy Manual Apprved Revised Plicy: D Nt Implement Until 3/2/19 Psitrn Emissin Tmgraphy (PET) fr Onclgic Applicatins DESCRIPTION Psitrn Emissin Tmgraphy (PET), als called PET imaging r a
More informationCnsideratin fr Optimizatin: Optimizatin is a prgram transfrmatin technique, which tries t imprve the cde by making it cnsume fewer resurces (i.e. CPU, Memry) and deliver high speed. In ptimizatin, high-level
More informationCOPD Outreach Program
COPD Outreach Prgram Wendy Laframbise, Advanced Practice Nurse Certified Respiratry Educatr COPD Outreach Prgram March, 2015 Disclaimer: The Canadian Fundatin fr Healthcare Imprvement (CFHI), in partnership
More informationNCI Version Date: (194) NSABP B-55/BIG 6-13
Figure 1 Study Flw Chart ICF fr patients with unknwn BRCA status t underg central BRCA testing during, r prir t, neadjuvant/adjuvant chemtherapy Neadjuvant chemtherapy Minimum 6 cycles (cntaining anthracyclines,
More informationIschemic heart disease (angina/chest pain)
Ischemic heart disease (angina/chest pain) External resurces Stable angina: management NICE guidelines [CG126] Updated :Aug 2016 https://www.nice.rg.uk/guidance/cg126 Chest pain f recent nset [CG95] Nvember
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationChronic Fatigue Syndrome
Chrnic Fatigue Syndrme (Als knwn as Myalgic encephalmyelitis/encephalmyelpathy) What is CFS/ME? CFS/ME cmprises a range f symptms that include fatigue, malaise, headaches, sleep disturbances, difficulties
More informationChallenges in the Treatment of Sinonasal Undifferentiated Carcinoma: A Ray of Hope
ORIGINft.-L ARTICLE Challenges in the Treatment f Sinnasal Undifferentiated Carcinma: A Ray f Hpe A N Nrleza, MBBS, B S Gendeh, MS ORL HNS Department f Otrhinlarynglgy, Head & Neck Surgery, Faculty f Medicine,
More informationPICO question In patients with glomerulonephritis what are patient preferences and values for immunosuppressive and non-immunosuppressive therapy?
KDIGO GN Guideline update Evidence summary Patient preferences fr glmerulnephritis treatment PICO questin In patients with glmerulnephritis what are patient preferences and values fr immunsuppressive and
More informationProstatitis - chronic - Management
Prstatitis - chrnic - Management Scenari: Diagnsis f chrnic prstatitis Hw shuld I diagnse chrnic prstatitis? Diagnse chrnic prstatitis if: The man has pain in the perineum r pelvic flr and lwer urinary
More information